{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:22:29Z","timestamp":1738387349755,"version":"3.35.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Medications for opioid use disorder are associated with a lower risk of drug overdoses at the individual level. However, little is known about whether these effects translate to population-level reductions. We investigated whether county-level efforts to increase access to medication for opioid use disorder in 2012\u20132014 were associated with opioid overdose deaths in New York State during the first years of the synthetic opioid crisis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We performed an ecologic county-level study including data from 60 counties (2010\u20132018). We calculated rates of people receiving medication for opioid use disorder among the population misusing opioids in 2012\u20132014 and categorized counties into quartiles of this exposure. We modeled synthetic and nonsynthetic opioid overdose death rates using Bayesian hierarchical models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Counties with higher rates of receiving medications for opioid use disorder in 2012-2014 had lower synthetic opioid overdose deaths in 2016 (highest vs. lowest quartile: rate ratio [RR] = 0.33, 95% credible interval [CrI] = 0.12, 0.98; and second-highest vs. lowest: RR = 0.20, 95% CrI = 0.07, 0.59) and 2017 (quartile second-highest vs. lowest: RR = 0.22, 95% CrI = 0.06, 0.83), but not 2018. There were no differences in nonsynthetic opioid overdose death rates comparing higher quartiles versus lowest quartile of exposure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A spatio-temporal modeling approach incorporating counts of the population misusing opioids provided information about trends and interventions in the target population. Higher rates of receiving medications for opioid use disorder in 2012\u20132014 were associated with lower rates of synthetic opioid overdose deaths early in the crisis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ede.0000000000001816","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T13:01:58Z","timestamp":1732280518000},"page":"186-195","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Rates of Receiving Medication for Opioid Use Disorder and Opioid Overdose Deaths During the Early Synthetic Opioid Crisis: A County-level Analysis"],"prefix":"10.1097","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3060-5994","authenticated-orcid":false,"given":"Julian","family":"Santaella-Tenorio","sequence":"first","affiliation":[{"name":"Department of Population Health, Center for Opioid Epidemiology and Policy, NYU Grossman School of Medicine, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadne","family":"Rivera-Aguirre","sequence":"additional","affiliation":[{"name":"Department of Population Health, Center for Opioid Epidemiology and Policy, NYU Grossman School of Medicine, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staci A.","family":"Hepler","sequence":"additional","affiliation":[{"name":"Department of Statistical Sciences, Wake Forest University, Winston-Salem, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cantor","sequence":"additional","affiliation":[{"name":"RAND Corporation, Santa Monica, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"DeYoreo","sequence":"additional","affiliation":[{"name":"RAND Corporation, Santa Monica, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia S.","family":"Martins","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Columbia University, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Krawczyk","sequence":"additional","affiliation":[{"name":"Department of Population Health, Center for Opioid Epidemiology and Policy, NYU Grossman School of Medicine, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Cerda","sequence":"additional","affiliation":[{"name":"Department of Population Health, Center for Opioid Epidemiology and Policy, NYU Grossman School of Medicine, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"R1-20250131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/science.aau1184","article-title":"Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016.","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"key":"R6-20250131","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths - United States, 2013-2017.","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R8-20250131","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies--tackling the opioid-overdose epidemic.","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-20250131","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","volume":"2","author":"Mattick","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20250131","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-20250131","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/10550887.2012.694603","article-title":"Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine\/naloxone in marginalized populations.","volume":"31","author":"Stancliff","year":"2012","journal-title":"J Addict Dis"},{"key":"R12-20250131","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.08.006","article-title":"Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial.","volume":"99","author":"Magura","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"R13-20250131","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial.","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"R15-20250131","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jsat.2018.12.003","article-title":"Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review.","volume":"99","author":"Moore","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"R16-20250131","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2017.11.023","article-title":"A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release.","volume":"184","author":"Brinkley-Rubinstein","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"R17-20250131","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system.","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"R18-20250131","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/add.15736","article-title":"Modeling the population level impact of opioid agonist treatment on mortality among people accessing treatment between 2001-2020 in New South Wales, Australia.","volume":"117","author":"Chaillon","year":"2022","journal-title":"Addiction"},{"key":"R19-20250131","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.amepre.2021.02.026","article-title":"Association between buprenorphine for opioid use disorder and mortality risk.","volume":"61","author":"Vakkalanka","year":"2021","journal-title":"Am J Prev Med"},{"key":"R20-20250131","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"R21-20250131","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"R22-20250131","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/add.14991","article-title":"Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.","volume":"115","author":"Krawczyk","year":"2020","journal-title":"Addiction"},{"key":"R23-20250131","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"R24-20250131","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/add.15959","article-title":"Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.","volume":"117","author":"Burns","year":"2022","journal-title":"Addiction"},{"key":"R27-20250131","doi-asserted-by":"crossref","first-page":"e32133","DOI":"10.2196\/32133","article-title":"Where opioid overdose patients live far from treatment: geospatial analysis of underserved populations in New York State.","volume":"8","author":"Abell-Hart","year":"2022","journal-title":"JMIR Public Health Surveill"},{"key":"R29-20250131","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","article-title":"A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction.","volume":"30","author":"Veilleux","year":"2010","journal-title":"Clin Psychol Rev"},{"key":"R30-20250131","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"key":"R31-20250131","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/aje\/kwae018","article-title":"Estimation of opioid misuse prevalence in New York State counties, 2007-2018. A Bayesian spatio-temporal abundance model approach.","volume":"193","author":"Santaella-Tenorio","year":"2024","journal-title":"Am J Epidemiol"},{"key":"R32-20250131","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jrsssa\/qnac013","article-title":"An integrated abundance model for estimating county-level prevalence of opioid misuse in Ohio.","volume":"186","author":"Hepler","year":"2023","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"R33-20250131","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/2041-210X.12329","article-title":"Estimates from non-replicated population surveys rely on critical assumptions.","volume":"6","author":"Knape","year":"2014","journal-title":"Methods Ecol Evol"},{"key":"R34-20250131","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.econlet.2012.06.001","article-title":"Identification issues in some double-index models for non-negative data.","volume":"117","author":"Papadopoulos","year":"2012","journal-title":"Econ Lett"},{"key":"R39-20250131","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/ADM.0000000000000820","article-title":"Utilization of medications for opioid use disorder across us states: relationship to treatment availability and overdose mortality.","volume":"16","author":"Krawczyk","year":"2022","journal-title":"J Addict Med"},{"key":"R40-20250131","doi-asserted-by":"crossref","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019.","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"key":"R41-20250131","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1526-4637.2011.01062.x","article-title":"Prescription drug monitoring programs and death rates from drug overdose.","volume":"12","author":"Paulozzi","year":"2011","journal-title":"Pain Med"},{"key":"R42-20250131","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/EDE.0000000000001609","article-title":"Changes in opioid and benzodiazepine poisoning deaths after cannabis legalization in the US: a county-level analysis, 2002-2020.","volume":"34","author":"Castillo-Carniglia","year":"2023","journal-title":"Epidemiology"},{"key":"R43-20250131","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/add.13543","article-title":"Prescription opioid poisoning across urban and rural areas: identifying vulnerable groups and geographic areas.","volume":"112","author":"Cerd\u00e1","year":"2017","journal-title":"Addiction"},{"key":"R44-20250131","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/EDE.0000000000001123","article-title":"Measuring relationships between proactive reporting state-level prescription drug monitoring programs and county-level fatal prescription opioid overdoses.","volume":"31","author":"Cerd\u00e1","year":"2020","journal-title":"Epidemiology"},{"key":"R47-20250131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1257\/pol.20170082","article-title":"Supply-side drug policy in the presence of substitutes: evidence from the introduction of abuse-deterrent opioids.","volume":"10","author":"Alpert","year":"2018","journal-title":"Am Econ J Econ Policy"},{"key":"R48-20250131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00116466","article-title":"Bayesian image restoration, with two applications in spatial statistics.","volume":"43","author":"Besag","year":"1991","journal-title":"Ann Inst Stat Math"},{"key":"R50-20250131","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/sim.4780142112","article-title":"Bayesian analysis of space-time variation in disease risk.","volume":"14","author":"Bernardinelli","year":"1995","journal-title":"Stat Med"},{"key":"R52-20250131","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of early medication treatment with retention in care among youths with opioid use disorder.","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatr"},{"key":"R53-20250131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/ADM.0000000000000374","article-title":"An innovative model for naloxone use within an OTP setting: a prospective cohort study.","volume":"12","author":"Katzman","year":"2018","journal-title":"J Addict Med"},{"key":"R55-20250131","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\u2013ethnicity and payment.","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiat"},{"key":"R56-20250131","doi-asserted-by":"crossref","first-page":"e203711","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States.","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R57-20250131","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.","volume":"40","author":"Hansen","year":"2013","journal-title":"J Behav Health Serv Res"},{"key":"R58-20250131","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugalcdep.2016.03.028","article-title":"Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City.","volume":"164","author":"Hansen","year":"2016","journal-title":"Drug Alcohol Depend"}],"container-title":["Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T13:05:43Z","timestamp":1738328743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/EDE.0000000000001816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ede.0000000000001816","relation":{},"ISSN":["1044-3983","1531-5487"],"issn-type":[{"type":"print","value":"1044-3983"},{"type":"electronic","value":"1531-5487"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}